factual

Myeloma treatment doubled patient survival

New myeloma drugs like Revlimid and Velcade have roughly doubled survival, turning a disease where patients lived an average of 3-4 years into one where patients can expect to live 7-10 years longer.

factualpending

Speaker

Vincent Rajkumar

Evidence Quote

“these drugs are great because they have doubled the survival”

Source

Vincent Rajkumar on the High Price of Cancer Drugs— EconTalk
Created: 6/13/2026, 12:13:30 AM

Your notes

Loading notes...